{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T07:10:31Z","timestamp":1767337831793,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ejso.2022.05.030","type":"journal-article","created":{"date-parts":[[2022,6,2]],"date-time":"2022-06-02T01:59:52Z","timestamp":1654135192000},"page":"1911-1921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1043-7401","authenticated-orcid":false,"given":"Simone","family":"Frassini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Calabretto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Granieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6227-9276","authenticated-orcid":false,"given":"Paola","family":"Fugazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-5475","authenticated-orcid":false,"given":"Jacopo","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4701-7534","authenticated-orcid":false,"given":"Nicola","family":"Fazzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-0307","authenticated-orcid":false,"given":"Luca","family":"Ansaloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Cobianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejso.2022.05.030_bib1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1186\/s12885-018-4610-4","article-title":"Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study","volume":"18","author":"Saad","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejso.2022.05.030_bib2","doi-asserted-by":"crossref","first-page":"12705","DOI":"10.2147\/OTT.S220971","article-title":"Locally advanced pancreatic ductal adenocarcinoma: challenges and progress","volume":"13","author":"Barcellini","year":"2020","journal-title":"OncoTargets Ther"},{"key":"10.1016\/j.ejso.2022.05.030_bib3","unstructured":"International Agency for Research on Cancer, World Health, Organization. Global Cancer Observatory 2018; Available from: URL: http:\/\/gco.iarc.fr\/"},{"key":"10.1016\/j.ejso.2022.05.030_bib4","article-title":"Pancreatic cancer: an increasing global public health concern","volume":"22","author":"Cabasag","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejso.2022.05.030_bib5","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"43","key":"10.1016\/j.ejso.2022.05.030_bib6","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","article-title":"Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes","volume":"24","author":"McGuigan","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.ejso.2022.05.030_bib7","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/MPA.0b013e318291fbc5","article-title":"Modest improvement in overall survival for patients with metastatic pancreatic cancer: a trend analysis using the surveillance, epidemiology, and end results registry from 1988 to 2008","volume":"42","author":"Worni","year":"2013","journal-title":"Pancreas"},{"issue":"1","key":"10.1016\/j.ejso.2022.05.030_bib8","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MPA.0b013e31825abf8c","article-title":"Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study","volume":"42","author":"Thomassen","year":"2013","journal-title":"Pancreas"},{"issue":"4","key":"10.1016\/j.ejso.2022.05.030_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in Oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"Suppl 5","key":"10.1016\/j.ejso.2022.05.030_bib10","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2022.05.030_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S1470-2045(05)70175-3","article-title":"Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial","volume":"6","author":"Reni","year":"2005","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2022.05.030_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ejso.2022.05.030_bib13","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/jso.25438","article-title":"Cytoreduction and hyperthermic intraperitoneal chemotherapy in metastatic colorectal cancer","volume":"119","author":"Eng","year":"2019","journal-title":"J\u00a0Surg Oncol"},{"issue":"21","key":"10.1016\/j.ejso.2022.05.030_bib14","article-title":"Prognostic impact of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer patients: a meta-analysis of randomized controlled trials","author":"Granieri","year":"2021","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2022.05.030_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejso.2022.05.030_bib16","article-title":"Amstar 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"15","key":"10.1016\/j.ejso.2022.05.030_bib17","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ejso.2022.05.030_bib18","series-title":"Assessing risk of bias in a non-randomized study","first-page":"621","author":"Sterne","year":"20192"},{"key":"10.1016\/j.ejso.2022.05.030_bib19","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejso.2022.05.030_bib20","article-title":"Levels of Evidence and grades of recommendation","author":"Phillips","year":"1998","journal-title":"Oxford Cent Evid Based Med"},{"year":"2012","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses","author":"Wells","key":"10.1016\/j.ejso.2022.05.030_bib21"},{"key":"10.1016\/j.ejso.2022.05.030_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","author":"Higgins","year":"2003","journal-title":"Br Med J"},{"year":"2019","series-title":"A\u00a0language and environment for statistical computing","author":"Team","key":"10.1016\/j.ejso.2022.05.030_bib23"},{"year":"2015","series-title":"An introduction to meta-analysis in R","author":"Schwarzer","key":"10.1016\/j.ejso.2022.05.030_bib24"},{"issue":"3","key":"10.1016\/j.ejso.2022.05.030_bib25","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Software"},{"key":"10.1016\/j.ejso.2022.05.030_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/bimj.201900036","article-title":"Meta-analysis of the difference of medians","author":"McGrath","year":"2020","journal-title":"Biom J"},{"key":"10.1016\/j.ejso.2022.05.030_bib27","unstructured":"Harrer M, Cuijpers P, Furukawa T., Ebert DD. Doing meta-analysis in R: a hands-on guide. Protect Lab."},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2022.05.030_bib28","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.21037\/jgo-20-46","article-title":"Hyperthermic intra-operative intraperitoneal chemotherapy as an adjuvant to pancreatic cancer resection","volume":"12","author":"Tentes","year":"2021","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2022.05.030_bib29","first-page":"482","article-title":"Cytoreduction and HIPEC for peritoneal carcinomatosis of pancreatic cancer","volume":"23","author":"Tentes","year":"2018","journal-title":"J\u00a0BUON"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2022.05.030_bib30","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.21037\/jgo-20-238","article-title":"Safety of perioperative hyperthermic intraperitoneal chemotherapy with gemcitabine in patients with resected pancreatic adenocarcinoma: a pilot study of the clinical trial EudraCT 2016-004298-41","volume":"12","author":"Padilla-Valverde","year":"2021","journal-title":"J\u00a0Gastrointest Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejso.2022.05.030_bib31","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.21037\/jgo-2020-02","article-title":"Intraperitoneal gemcitabine chemotherapy is safe for patients with resected pancreatic cancer: final clinical and pharmacologic data from a phase II protocol and recommended future directions","volume":"12","author":"Sugarbaker","year":"2021","journal-title":"J\u00a0Gastrointest Oncol"},{"key":"10.1016\/j.ejso.2022.05.030_bib32","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920940887","article-title":"Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma","volume":"12","author":"Di Giorgio","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2022.05.030_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/jclinpath-2020-206607","article-title":"Next-generation sequencing and histological response assessment in peritoneal metastasis from pancreatic cancer treated with PIPAC","volume":"74","author":"Nielsen","year":"2021","journal-title":"J\u00a0Clin Pathol"},{"issue":"5","key":"10.1016\/j.ejso.2022.05.030_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10585-017-9849-7","article-title":"Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC)","volume":"34","author":"Graversen","year":"2017","journal-title":"Clin Exp Metastasis"},{"issue":"10","key":"10.1016\/j.ejso.2022.05.030_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186709","article-title":"Pressurized Intra Peritoneal Aerosol Chemotherapy in patients suffering from peritoneal carcinomatosis of pancreatic adenocarcinoma","volume":"12","author":"Khosrawipour","year":"2017","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.ejso.2022.05.030_bib36","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/bjs.11792","article-title":"Phase I\/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis","volume":"107","author":"Yamada","year":"2020","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.ejso.2022.05.030_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10637-020-00982-7","article-title":"A\u00a0phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis","volume":"39","author":"Takahara","year":"2021","journal-title":"Invest N Drugs"},{"issue":"5","key":"10.1016\/j.ejso.2022.05.030_bib38","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1007\/s10637-016-0369-0","article-title":"Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites","volume":"34","author":"Takahara","year":"2016","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.ejso.2022.05.030_bib39","unstructured":"https:\/\/www.assessurgery.com\/clavien-dindo-classification\/"},{"issue":"2","key":"10.1016\/j.ejso.2022.05.030_bib40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.2174\/157489209788452876","article-title":"Rationale for an intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer","volume":"4","author":"Kamath","year":"2009","journal-title":"Recent Pat Anti-Cancer Drug Discov"},{"issue":"3","key":"10.1016\/j.ejso.2022.05.030_bib41","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5858\/133.3.413","article-title":"The pathology and genetics of metastatic pancreatic cancer","volume":"133","author":"Yachida","year":"2009","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.ejso.2022.05.030_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.suronc.2017.01.002","article-title":"Strategies to improve local control of resected pancreas adenocarcinoma","volume":"26","author":"Sugarbaker","year":"2017","journal-title":"Surg Oncol"},{"issue":"41","key":"10.1016\/j.ejso.2022.05.030_bib43","doi-asserted-by":"crossref","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","article-title":"Peritoneal carcinomatosis","volume":"19","author":"Coccolini","year":"2013","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ejso.2022.05.030_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(05)70539-8","article-title":"New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?","volume":"7","author":"Sugarbaker","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2022.05.030_bib45","article-title":"Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study","volume":"24","author":"Kurtz","year":"2018","journal-title":"Gastroenterol Res Pract"},{"issue":"1","key":"10.1016\/j.ejso.2022.05.030_bib46","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12885-020-6572-6","article-title":"Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review","volume":"20","author":"Ploug","year":"2020","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ejso.2022.05.030_bib47","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11912-018-0703-0","article-title":"Peritoneal metastases from gastrointestinal cancer","volume":"20","author":"Sugarbaker","year":"2018","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"10.1016\/j.ejso.2022.05.030_bib48","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/02656736.2016.1227094","article-title":"The effect of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) as an adjuvant in patients with resectable pancreatic cancer","volume":"32","author":"Tentes","year":"2016","journal-title":"Int J Hyperther"},{"issue":"2","key":"10.1016\/j.ejso.2022.05.030_bib49","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10585-021-10074-2","article-title":"The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review","volume":"38","author":"Brind'Amour","year":"2021","journal-title":"Clin Exp Metastasis"},{"issue":"4","key":"10.1016\/j.ejso.2022.05.030_bib50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3892\/ol.2021.12507","article-title":"Place of hyperthermic intraperitoneal chemotherapy in the armament against pancreatic adenocarcinoma: a survival, mortality and morbidity systematic review","volume":"21","author":"Larentzakis","year":"2021","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ejso.2022.05.030_bib51","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER\u2217Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2020 Sub (1975-2018), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2021, based on the November 2020 submission."},{"issue":"19","key":"10.1016\/j.ejso.2022.05.030_bib52","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"Groupe tumeurs digestives of unicancer; PRODIGE intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.ejso.2022.05.030_bib53","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ejso.2022.05.030_bib54","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1245\/s10434-018-6558-7","article-title":"Implications of the pattern of disease recurrence on survival following pancreatectomy for pancreatic ductal adenocarcinoma","volume":"25","author":"Groot","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2022.05.030_bib55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13193-016-0504-6","article-title":"Complications of cytoreductive surgery and HIPEC in the treatment of peritoneal metastases","volume":"7","author":"Mehta","year":"2016","journal-title":"Indian J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2022.05.030_bib56","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1245\/s10434-014-4186-4","article-title":"A\u00a0comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion","volume":"22","author":"Downs-Canner","year":"2015","journal-title":"Ann Surg Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798322004802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798322004802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:43:16Z","timestamp":1760060596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798322004802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0748798322004802"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2022.05.030","relation":{},"ISSN":["0748-7983"],"issn-type":[{"type":"print","value":"0748-7983"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2022.05.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}